Regeneron And Intellia Therapeutics Expand Collaboration To Develop CRISPR/Cas9-Based Treatments; Intellia To Receive Upfront Payment Of $70M, And Regeneron Will Make An Additional Equity Investment In Intellia Of $30M At $32.42 Per Share
Benzinga Newsdesk